As expected, Neos Therapeutics Inc. received a complete response letter (CRL) for Cotempla XR-ODT, its orally disintegrating tablet (ODT) version of methylphenidate, delaying its commercial foray into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results